Triplet Therapeutics launches with $59 million to develop antisense therapies for Huntington's and more
Tuesday, December 17, 2019 - 06:20
in Health & Medicine
The startup believes a single target could stall the development of dozens of triplet-repeat diseases, including Huntington's and myotonic dystrophy